Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aethlon Medical Inc AEMD

Healthcare Medical Devices
Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.


NDAQ:AEMD - Post by User

Aethlon Medical Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(229)
•••
Post by whytestockson Sep 19, 2024 2:45pm
24 Views
Post# 36231561

Immunotherapy Clinical Trials - A New Approach to Treating C

Immunotherapy Clinical Trials - A New Approach to Treating C
News; $AEMD Immunotherapy Clinical Trials - A New Approach to Treating CancerVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 19, 2024) - Investorideas.com , a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, featuring Ae...AEMD - Immunotherapy Clinical Trials - A New Approach to Treating Cancer

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities